title: HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.
abstract: One hundred fifty patients with toxic and scintigraphically diffuse goiter were HLA typed (A, B, C, DR). One group consisted of 101 patients with concomitant Graves' ophthalmopathy and/or TSH-binding inhibiting antibodies (TBIAb). Forty nine patients had neither ophthalmopathy nor TBIAb. The former group showed a higher prevalence of HLA-B8 and DR3 compared to a normal control group. The latter group showed a higher frequency of HLA-DR5, whereas the HLA-B8 and DR3 antigens were slightly below normal prevalence. These data indicate an immunogenetic heterogeneity in patients with toxic diffuse goiter. A group of 47 hyperthyroid patients with single autonomous thyroid adenoma had no increased prevalence of any HLA-antigens. Patients with long term remission did not show an altered prevalence of any of the HLA antigens compared to controls. In contrast, patients with Graves' ophthalmopathy and/or TBIAb activity who relapsed had a significantly higher prevalence of HLA-B8 DR3, whereas patients without TBIAb and eye signs who relapsed had a significantly higher prevalence of HLA-DR5 than the control group.
mesh_terms: D006111:Graves Disease / Q000235:genetics / Q000276:immunology*; D006680:HLA Antigens / Q000032:analysis; D015795:HLA-B8 Antigen; D015803:HLA-DR3 Antigen; D015805:HLA-DR5 Antigen; D000949:Histocompatibility Antigens Class II / Q000032:analysis*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D018828:Immunoglobulins, Thyroid-Stimulating
chemical_list: D006680:HLA Antigens; D015795:HLA-B8 Antigen; D015803:HLA-DR3 Antigen; D015805:HLA-DR5 Antigen; D000949:Histocompatibility Antigens Class II; D007074:Immunoglobulin G; D018828:Immunoglobulins, Thyroid-Stimulating